Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals

#1303

Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.

Aim(s): To determine real-world costs of two therapies for mGEP-NETs.

Materials and methods: A hypothetical cohort of 500 GEP-NET patients is considered the treated population in the model, with the proportion treated with an SSA estimated using published epidemiologic data. Drug acquisition, preparation, dosing and administration costs are included based on a national pricing database and published literature. Published estimates of real-world dosing of octreotide (OCT) are utilized as a model assumption. As LAN was approved recently, real-world dosing was unavailable and the model assumed labeled dosing.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Pulgar S

Authors: Ortendahl J, Pulgar S, Cox D, Bentley T, Phan A,

Keywords: GEP-NETs, budget impact, somatostatin, lanreotide,